Nicholas from Poland

Registered at the short selling broker Skilling, 3 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Eli Lilly & Co. (LLY) shares information

Eli Lilly & Co.


24h Change

0.52 %

LLY

Live rate: Market closed

Stock data per Friday 23 Oct, 2020

LLY
New York Stock Exchange
141.65
142
142.38
0.73 (+ 0.52%)
US Market is closed

Live Stock price in graph for Eli Lilly & Co. (LLY)

  • Latest Volume

    2,427,462 (-20.61 %)

  • Volume prev. day

    3,057,821

  • Avg. daily volume

    3,710,471

  • Market cap

    136,182,198,600

  • P/E ratio

    23.09

  • Today high

    144.72

  • Today low

    141.72

  • 52 week high

    170.75

  • 52 week low

    106.25

  • YTD Change

    + 8.21 %

Quick links

Broker recommendations for Eli Lilly & Co.

The Eli Lilly & Co. stock is rated at 1.375 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Wednesday 21 October, 2020 by a total of 16 brokers. This means that the consensus of the 16 different brokers is leaning toward to buy/moderate buy.

Sell
0 (0%)
Underweight
0 (0%)
Hold
6 (37.5%)
Overweight
0 (0%)
Buy
10 (62.5%)

Price target by analysts

The 14 latest analyst estimates, per Wednesday 21 October, 2020, show the following high, low and average price targets.
Target Average: 172.36 USD
Target High: 200 USD
Target Low: 144 USD

 

Latest news about Eli Lilly & Co.

Below you can find the most recent news posts about Eli Lilly & Co., primarily from US and UK based news sources.

Eli Lilly And Co (NYSE:LLY) Coverage Initiated by Analysts at Truist

Saturday, 24 October 2020, 14:55:11
Truist assumed coverage on shares of Eli Lilly And Co (NYSE:LLY) in a research report sent to investors on Friday morning, The Fly reports. The firm issued a buy rating and a $180.00 price target on the stock. A number of other equities research analysts have also issued reports on LLY. Morgan Stanley raised shares […]
— Transcript Daily


Gilead is set to sell billions of dollars of a coronavirus drug that’s far from ‘amazing’ after the US approved remdesivir to treat COVID-19

Saturday, 24 October 2020, 13:05:00
Summary List Placement The first approval of a COVID-19 drug in the US wasn’t quite a cause for celebration. US regulators approved the virus-fighting drug remdesivir on Thursday, greenlighting its use in hospitalized patients. The US Food and Drug Administration had given an emergency OK for the drug’s use in May. But it’s unclear how well remdesivir, marketed as Veklury, works for patients with COVID-19, the disease caused by the novel coronavirus. Studies respectively led by the US National Institutes of Health and the World Health Organization came to conflicting conclusions, with the WHO research casting doubt on the drug’s benefits. “It has an effect, but it doesn’t really have an amazing effect that people were hoping it would have,” Dr. Walid Gellad, director for the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh, told Business Insider in a Friday phone interview. In squaring the findings of the main studies on remdesivir, longtime drug discovery researcher Derek Lowe wrote that “for remdesivir, it looks like the argument now is ‘Does it help a bit or just not at all?'” Despite that uncertainty, one thing is clear: Remdesivir’s manufacturer, the California biotech giant Gilead Sciences, is in a prime position to sell billions of dollars worth of the drug.
— Business Insider


Livestock Animal Vaccine Market Research and Share by Forecast 2020-2025 | Merck, Zoetis, Boehringer Ingelheim, Ceva, CAHIC, HVRI, Ringpu Biology, Yebio, DHN, WINSUN, Elanco/Eli Lilly

Friday, 23 October 2020, 17:46:33
This report provides in-depth study on the current state of the Global Livestock Animal Vaccine Market 2020-2025. Key players in the Global Livestock Animal Vaccine Market have been identified through the secondary research and their market share has been determined
— OpenPR


Active Pharmaceutical Ingredients (API) Market Size 2020 Industry Price Trend, Industry Outlook, Business Growth, Report Latest Research| Pfizer Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company

Friday, 23 October 2020, 09:21:18
The Active Pharmaceutical Ingredients (API) Market Research Report delivers all-inclusive analysis of the market structure along with forecast of the diverse segments and sub-segments of the market. Active Pharmaceutical Ingredients (API) Market 2020 Industry Research Report is an in-depth and
— OpenPR


FDA Approves Gilead’s Remdesivir To Treat COVID-19 Despite Data Showing Drug Doesn’t Work

Friday, 23 October 2020, 00:00:00
FDA Approves Gilead’s Remdesivir To Treat COVID-19 Despite Data Showing Drug Doesn’t Work Tyler Durden Thu, 10/22/2020 – 18:00 Despite reams of data from an international WHO study raising serious questions about its efficacy, the FDA has finally approved the use of Gilead Science’s remdesivir – a powerful antiviral originally developed to treat ebola – for the treatment of COVID-19, making it the first such drug approved to treat the virus in the US. The FDA first granted the drug emergency authorization in May, allowing hospitals and doctors to use the drug even though by all accounts it wasn’t that widely used. President Trump received one course of remdesivir along with several other COVID-19 therapies after contracting the virus. Doctors also gave the president dexamethasone, a steroid that has a much better track record for treating the virus, according to the available data. Trump also received an experimental drug from Regeneron, which, along with Eli Lilly, has filed for emergency use approval for its COVID-19 antibody treatment.
— Zero Hedge


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €/$ 20
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have LLY available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.